Kura Oncology (KURA) Other financing activities (2017 - 2026)

Kura Oncology (KURA) has 10 years of Other financing activities data on file, last reported at $69000.0 in Q1 2026.

• On a quarterly basis, Other financing activities fell 51.75% year-over-year to $69000.0 in Q1 2026; TTM through Mar 2026 was $1.7 million, a 72.24% decrease from a year earlier, with the FY2025 full-year figure at $1.8 million, down 79.16% from the prior year.
• Other financing activities for Q1 2026 stood at $69000.0, down from $1.1 million in the prior quarter.
• Over the last five years, Other financing activities for KURA reached as high as $3.0 million in Q2 2024 and fell as low as $69000.0 in Q1 2026.
• Historically, Other financing activities has averaged $1.1 million across 5 years, with a median of $749000.0 in 2023.
• Across the five-year window, Other financing activities surged 2521.43% in 2024 and sank 94.4% in 2025, its largest moves.
• Year by year, Other financing activities stood at $567000.0 in 2022, then climbed by 21.87% to $691000.0 in 2023, then rose by 16.79% to $807000.0 in 2024, then soared by 40.64% to $1.1 million in 2025, then tumbled by 93.92% to $69000.0 in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $69000.0 in Q1 2026, $1.1 million in Q4 2025, and $515000.0 in Q2 2025.